Outcomes differ in patients who undergo immediate intraoperative revision versus patients with delayed postoperative revision of residual lesions in congenital heart operations  by Nathan, Meena et al.
Congenital Heart Disease Nathan et al
C
H
DOutcomes differ in patients who undergo immediate intraoperative
revision versus patients with delayed postoperative revision
of residual lesions in congenital heart operationsMeena Nathan, MD,a Kimberlee Gauvreau, ScD,b Hua Liu, MS,a Frank A. Pigula, MD,a
John E. Mayer, MD,a Steven D. Colan, MD,b and Pedro J. del Nido, MDaFrom th
Hosp
Disclosu
Read at
Surge
Receive
public
Address
Child
02215
0022-52
Copyrig
http://dx
2540Objectives: In a previous study of infants less than 6 month old, we found that delayed revision of residual
lesions resulted in worse patient outcomes compared with intraoperative revision. We explored a larger cohort
to determine if this finding persisted.
Methods:A prospective cohort followed from index surgery to discharge from January 2011 to September 2013
were divided into 4 groups: (1) intraoperative revisions (IO) of residual lesions, (2) delayed postoperative revi-
sion (PO) of residual lesions during the same hospital stay, (3) both intraoperative and delayed (BOTH) revision
of residual lesions, (4) no intraoperative or postoperative revision (NO). Linear and logistic regression analyses
were used to compare outcomes of postoperative hospital length of stay, postoperative adverse events (AE),
hospital costs, and mortality, after adjusting for age, prematurity, presence of extracardiac anomalies, and
RACHS-1 (Risk Adjustment for Congenital Heart Surgery-1) risk category known to affect outcomes.
Results: Of the 2427 patients discharged after a congenital cardiac operation, 1886 were eligible for this study
after exclusion of adults, procedures performed off cardiopulmonary bypass, and transplants and assist devices.
On multivariable modeling adjusting for other significant patient factors, the NO group fared better than the
other 3 groups. The IO group had significantly lower postoperative length of stay, AE rate, and hospital costs
compared with the PO and BOTH groups, but showed no significant differences in mortality.
Conclusions: Intraoperative correction of residual lesions results in shorter length of stay, and lower postoper-
ative AE and costs compared with delayed postoperative revision of residual lesions. (J Thorac Cardiovasc Surg
2014;148:2540-7)See related commentary on pages 2548-9.Supplemental material is available online.
Outcomes after congenital cardiac surgery depend on
multiple factors including preoperative, intraoperative,
and postoperative factors and events.1-3 Technical
adequacy of repair is likely a significant determinant of a
successful outcome.4-13 A technically optimal result may
sometimes require intraoperative revision of residual
defects. In addition, a technically optimal repair may bee Departments of Cardiac Surgerya and Cardiology,b Boston Children’s
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The Journal of Thoracic and Cardiovascular Surable to neutralize the detrimental effects of poor
preoperative physiology or case complexity.6 In previous
work on a group of infants less than 6 months of age at
surgery,7 we were able to demonstrate that intraoperative
recognition and correction of major residual defects
resulted in better outcomes, even at the expense of a second
bypass run with resultant longer support and ischemic
times. We wished to determine if this remained true in a
larger cohort of patients encompassing a wide range of
age and disease complexity.METHODS
Consecutive patients who were discharged after congenital heart sur-
gery from January 2011 to September 2013 were followed prospectively
from admission to discharge with institutional review board approval.
We excluded patients aged 18 years or more, procedures performed off
cardiopulmonary bypass, and transplants and assist devices. Only the in-
dex surgery for each admission was included in the analysis. The Risk
Adjustment for Congenital Heart Surgery-1 (RACHS-1) categories14,15
and the Society of Thoracic Surgeons–European Association for
Cardio-Thoracic Surgery (STAT) mortality categories16,17 were used to
determine case complexity. The occurrence of intraoperative
reintervention for residual defects, and postoperative unplanned
reinterventions for residual defects in anatomic areas operated at the
index surgery were recorded. Major postoperative adverse events
(AEs) as defined by the Society of Thoracic Surgeons (STS) congenital
heart surgery database criteria (excluding unplanned reinterventions in
the anatomic area of repair at index surgery), mortality, postoperativegery c December 2014
Abbreviations and Acronyms
AE ¼ adverse event
BOTH ¼ both intraoperative and delayed
postoperative revision
EACTS ¼ European Association for Cardio-
Thoracic Surgery
IO ¼ intraoperative revision
NO ¼ no intraoperative or postoperative
revision
PO ¼ delayed postoperative revision
RACHS-1 ¼ risk adjustment in congenital heart
surgery
STAT ¼ Society of Thoracic Surgeons–
European Association for Cardio-
Thoracic Surgery mortality categories
STS ¼ Society of Thoracic Surgeons
TEE ¼ transesophageal echocardiography
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Dlength of hospital stay, and total hospital costs were obtained. Additional
information on risk factors such as prematurity, presence
of chromosomal and other noncardiac anomalies, and patient
demographics such as age and gender were documented.
Categorization of Revisions for Residual Lesions
(Revision Groups)
The entire patient cohort was categorized into 4 groups: (1) intraopera-
tive revision (IO) of residual lesions, (2) delayed postoperative revision
(PO) of residual lesions during the same hospital stay, (3) both intraopera-
tive and delayed (BOTH) revision of residual lesions, (4) no intraoperative
or postoperative revisions (NO).
RACHS-1 Risk Categories
The RACHS-1 method was developed to adjust for baseline case mix
differences in risk when comparing in-hospital mortality among groups
of patients less than 18 years of age undergoing congenital heart surgery.
Surgical procedures were placed into 6 predefined categories with similar
risks for in-hospital mortality; category 1 had the lowest risk for death and
category 6 the highest. Cases with combinations of cardiac surgical
procedures (eg, repair of coarctation of the aorta and ventricular septal
defect closure) were placed in the risk category corresponding to the single
highest risk procedure.14,15 In order to be able to evaluate the entire study
cohort, including those for whom the original RACHS-1 method was not
validated, we used category 7 to represent patients who underwent a
cardiac surgical procedure that was not included in the RACHS-1
method (eg, biventricular recruitment, biventricular conversion from
single-ventricle palliation, and so forth).
STAT Mortality Categories
STAT mortality categories were developed using a Bayesian model
based on more than 75,000 congenital cardiac operations entered either
in the STS congenital heart surgery database or the congenital heart surgery
databases of the European Association for Cardio-Thoracic Surgery
(EACTS) between 2002 and 2007.16,17 Congenital cardiac operations
were divided into 5 homogeneous categories with increasing risk of
mortality. This method of risk stratification was further validated in
subsequent studies and is currently used for risk stratification in the STS
and EACTS congenital heart surgery database analyses for patients of allThe Journal of Thoracic and Carages. STAT category 1 has the lowest risk of mortality and STAT
category 5 has the highest risk of mortality. For the purposes of this
study, an additional category (category 6) was created to include all
procedures that could not be assigned to the existing STAT categories
(eg, biventricular conversion after single-ventricle palliation).
Outcomes
The primary outcome of interest was postoperative hospital length of
stay. The secondary outcomes included in this analysis were major
postoperative AEs, early mortality, and total hospital costs. Postoperative
hospital length of stay was defined as length of hospital stay beginning
from the day of index surgery until discharge from hospital. Early mortality
was defined as death while in hospital or death within 30 days of index
operation if discharged before 30 days.18 Major postoperative AEs were
defined according to the STS congenital heart surgery database classifica-
tion19 and included the following: (1) need for extracorporeal membrane
oxygenator support, (2) reexploration for bleeding, (3) cardiac arrest
requiring resuscitation, (4) reexploration for hemodynamic instability, (5)
diaphragm plication for paralysis/paresis of the diaphragm, (6) stroke,
(7) mediastinitis requiring exploration and debridement, and (8) renal
failure requiring dialysis. Unplanned surgical or catheter-based reinterven-
tions in the anatomic area operated on and placement of permanent
pacemakers were not included as AEs as they are used to define the revision
groups. Hospital charges for each surgical admission were obtained from
the hospital’s cost accounting database. Costs were then calculated based
on the cost to charge ratio for each fiscal year.
Statistical Analysis
Categorical variables are summarized as numbers and percentages, and
continuous variables as medians and ranges or interquartile range as
indicated. Patient risk factors and outcomes were compared across the 4
revision groups using the c2 test for categorical variables and the
Kruskal-Wallis test for continuous variables. In order to adjust for baseline
patient characteristics when examining differences in outcomes among the
4 revision groups, multivariable logistic and linear regression analyseswere
used. Intraoperative revisions were used as the reference category and
indicator variables were created for each of the 3 other revision groups.
Discrimination of the logistic regression models for predicting mortality
and major postoperative AEs was assessed using the area under the
receiver-operator characteristic curve. For the linear regression model for
postoperative hospital length of stay and total hospital costs, the coefficient
of determination is presented. Because both postoperative hospital length of
stay and total hospital cost have skewed distributions, a log transformation
was applied. Regression coefficients and odds ratios are presented with
95% confidence intervals. SAS version 9.2 (SAS Institute Inc, Cary, NC)
was used for the statistical analysis.
RESULTS
There were 1886 eligible patients included in the study
from 2427 consecutive patient discharges between January
2011 and September 2013. Among the entire cohort, 829
(44%) were girls. The median age was 1.2 years (range,
0 days to 17.9 years); 145 (8%) were premature, and 390
(21%) had some form of extracardiac congenital anomaly
or genetic anomaly. The distribution among the RACHS-1
risk categories was as follows: 164 (9%) category 1, 586
(31%) category 2, 676 (36%) category 3, 208 (11%)
category 4, 71 (4%) category 6, and 181 (10%) category 7
(no RACHS category). The distribution among the STAT
categories was as follows: 650 (34%) category 1, 525
(28%) category 2, 183 (10%) category 3, 376 (20%)diovascular Surgery c Volume 148, Number 6 2541
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Dcategory 4, 105 (6%) category 5, and 47 (2%) category 6 (no
STAT category). The distribution of the revision categories
was as follows: 1658 (88%) NO, 81 (4%) IO, 128 (7%)
PO, and 19 (1%) BOTH. The baseline patient characteristics
among the 4 revision groups and outcomes of interest are
represented in Table 1. The types of intraoperative and post-
operative revisions in the IO, PO, and BOTH groups are
shown in the Online Data Supplement Tables E1 to E3.The
median postoperative hospital length of stay was 7 days
(25th and 75th percentiles, 5 and 13 days, respectively); the
AE rate, excluding unplanned surgical or catheter-based
reinterventions in the anatomic area repaired at the index
operation, was 5.3% (100); and the mortality rate was
2.1% (39). The hospital costs are represented in Table 1.Postoperative Hospital Length of Stay
Postoperative hospital length of stay varied across the 4
revision groups, with the PO and BOTH groups having
longer median length of stay than the NO and IO groups
(P< .001, Table 1, Figure E1). Patient factors associated
with longer length of stay were neonatal age, prematurity,TABLE 1. Patient characteristics and outcomes by the 4 revision groups (
No revisions
Intraoperativ
revision of resid
lesion
Number in group (%) 1658 (88) 81 (4)
Median age, y (range) 1.3 (1 d-17.9) 1.9 (1 d-16.5)
Prematurity, n (%) 119 (7) 5 (6)
Extracardiac/genetic
anomalies/syndromes, n (%)
333 (20) 21 (26)
RACHS-1 risk category, n (%)
1 (164) 160 (10) 3 (4)
2 (586) 543 (33) 25 (31)
3 (676) 580 (35) 41 (51)
4 (208) 172 (10) 8 (10)
6 (71) 58 (4) 0 (0)
Not categorized, 7 (181) 145 (9) 4 (5)
STAT mortality category, n (%)
1 (650) 619 (37) 21 (26)
2 (525) 461 (28) 31 (38)
3 (183) 159 (10) 10 (12)
4 (376) 293 (18) 16 (20)
5 (105) 86 (5) 2 (2)
6 (47) (not categorized) 40 (2) 1 (1)
Median postoperative hospital
length of stay, d (25th, 75th
percentiles)
6 (4, 11) 7 (5, 11)
Postoperative adverse
events, n (%)
48 (2.9) 3 (3.7)
Early mortality, n (%) 13 (0.8) 3 (3.7)
Median total hospital costs,
US$ (25th, 75th percentiles)
44,504 (32,134, 78,342) 49,427 (37,552, 81
Postoperative adverse events exclude unplanned postoperative reinterventions in the anatom
Thoracic Surgeons Congenital Database list. RACHS-1, Risk adjustment for congenit
Cardio-Thoracic Surgery mortality categories.
2542 The Journal of Thoracic and Cardiovascular Surhigher RACHS-1 risk category or STAT mortality
category, and the presence of chromosomal or other
extracardiac anomalies (Table E4). After adjusting for
significant baseline patient characteristics, both the PO
and BOTH revision groups had significantly longer length
of stay than the IO group (P < .001 and P ¼ .001
respectively); the NO group had significantly shorter
length of stay (P ¼ .028) (Table 2).Postoperative AEs
Similarly, postoperative AEs varied significantly across
the 4 revision groups; the PO and BOTH groups
experienced a greater proportion of events than the NO
and IO groups (Table 1, Figure E1). Other factors associated
with postoperative AEs were younger age, higher
RACHS-1 or STAT category, prematurity, and chromo-
somal or extracardiac abnormality (P ¼ .03 for anomalies
and P< .001 for the rest; Table E4). After adjusting for
significant patient risk factors, compared with the IO group,
the PO and BOTH groups remained strongly associated
with postoperative AEs (Table 3).n ¼ 1886)
e
ual
Postoperative
revision of residual
lesion
Both intra- and
postoperative revision
of residual lesion P value
128 (7) 19 (1)
0.5 (1 d-15.5) 0.7 (2 d-14.5) <.001
21 (16) 0 (0) .004
29 (23) 7 (37) .16
<.001
1 (1) 0 (0)
18 (14) 0 (0)
45 (35) 10 (53)
26 (20) 2 (11)
11 (9) 2 (11)
27 (21) 5 (26)
<.001
10 (8) 0 (0)
30 (23) 3 (16)
10 (8) 4 (21)
59 (46) 8 (42)
15 (12) 2 (11)
4 (3) 2 (11)
26 (14, 63) 17 (12, 30) <.001
43 (34) 6 (32) <.001
19 (15) 4 (21) <.001
,592) 204,750 (99,061, 427,594) 202,026 (109,115, 345,505) <.001
ic area of repair but include all other major complications specified by the Society of
al heart surgery; STAT, Society of Thoracic Surgeons–European Association for
gery c December 2014
TABLE 2. Multivariable linear regression model for outcome
postoperative hospital length of stay
Regression
coefficient 95% CI P value
Extracardiac/genetic
anomalies/syndromes
1.2 1.1-1.3 <.001
Prematurity 1.4 1.3-1.5 <.001
Neonates (30 d) 1.9 1.8-2.1 <.001
Infants (31 d to<1 y) 1.4 1.3-1.5 <.001
RACHS-1 risk categories
1 (reference) 1.0 — —
2 1.3 1.2-1.5 <.001
3 1.9 1.7-2.1 <.001
4 2.1 1.9-2.4 <.001
6 3.4 2.9-4.1 <.001
7 (not categorized) 2.7 2.4-3.1 <.001
Revision groups: reintervention
for residual lesions
Intraoperative reintervention
(reference)
1.0 — —
No reintervention 0.9 0.8-1.0 .028
Postoperative reintervention 2.5 2.1-2.9 <.001
Both intraoperative and
postoperative reinterventions
1.6 1.2-2.2 .001
Coefficient of determination is R2 ¼ 40.2% for the model that does not contain
revision groups, and increases to R2 ¼ 50.2% when revision groups are included.
CI, Confidence interval; RACHS-1, risk adjustment for congenital heart surgery.
TABLE 3. Multivariable logistic regression model for outcome major
postoperative adverse events
Odds
ratio 95% CI P value
Extracardiac/genetic
anomalies/syndromes
1.1 0.6-1.9 .71
Prematurity 4.9 2.6-8.9 <.001
Neonates (30 d) 3.0 1.4-6.4 .004
Infants (31 d to<1 y) 1.7 0.9-3.4 .10
RACHS-1 risk categories
1 þ 2 (reference) 1.0 — —
3 1.8 0.9-4.0 .12
4 4.4 1.9-10.5 <.001
6 9.1 3.2-25.8 <.001
7 (not categorized) 4.8 2.1-11.0 <.001
Revision groups: reintervention for
residual lesions
Intraoperative reintervention (ref) 1.0 — —
No reintervention 0.7 0.2-2.3 .49
Postoperative reintervention 7.4 2.0-27.7 .003
Both intraoperative and postoperative
reinterventions
9.2 1.8-47.3 .008
Major postoperative adverse events exclude unplanned surgical or catheter-based
reinterventions in anatomic area of repair at the index surgery. c statistic is 0.822
for the model that does not contain revision groups, and increases to 0.879 when
revision groups are included. CI, Confidence interval; RACHS-1, risk adjustment
for congenital heart surgery.
Nathan et al Congenital Heart Disease
C
H
DEarly Mortality
Similarly, early mortality (30-day or in-hospital mortal-
ity) varied significantly across the 4 revision groups; the
PO and BOTH groups had a higher mortality rate than the
NO and IO groups (Table 1, Figure E1). Other variables
associated with mortality included younger age, higher
RACHS-1 or STAT category, prematurity, and the presence
of chromosomal or other extracardiac anomalies (all P 
.001, Table E4). Adjusting for variables significant in uni-
variate analysis and comparing the IO group with the other
groups, the NO group had significantly lower mortality
(P ¼ .02). However, there was no significantly higher asso-
ciation with mortality for the PO or BOTH groups (Table 4).
The odds ratios were 2.1 and 5.5 for the PO and BOTH
groups, respectively, compared with the IO group, and the
BOTH group showed a trend toward significance (P¼ .08).Total Hospital Costs
Total hospital costs varied across the 4 revision groups;
the PO and BOTH groups had higher total hospital costs
than the NO and IO groups (P < .001, Table 1,
Figure E1). Other factors associated with longer length of
stay were neonatal age, prematurity, higher RACHS-1 or
STAT category, and the presence of chromosomal or other
extracardiac anomalies (Table E4). After adjusting for sig-
nificant baseline patient characteristics, both the PO and
BOTH revision groups had significantly higher totalThe Journal of Thoracic and Carhospital costs than the IO group (P< .001), whereas the
NO group had significantly lower total hospital costs than
the IO group (P ¼ .004) (Table 5).
For all outcomes, the findings were similar when
RACHS-1 risk categories were replaced by STAT mortality
categories in the multivariable models. On further analysis
of the 81 patients who underwent intraoperative revisions
only, 68 (84%) left the hospital with an adequate or better
repair on the discharge echocardiogram. Most patients, 55
of the 81 (68%), who underwent successful intraoperative
revisions were in RACHS-1 categories 2 and 3 (predomi-
nantly valve repair related), clearly indicating the impor-
tance of optimal and complete intraoperative imaging to
help to determine the adequacy of the repair.Subgroup Analysis
We performed the following additional subgroup ana-
lyses as exploratory analyses to look for trends. The
BOTH group was excluded because of small sample size.
The findings of the univariate analysis are presented in
Table E5.
Risk-adjusted subgroup analysis by the presence or
absence of valve intervention. Restricting to patients
who had valve interventions at the index surgery, the rela-
tionships were similar to those in the overall cohort with
the exception that there was no significant difference be-
tween the IO and NO groups for the outcomes of interest.diovascular Surgery c Volume 148, Number 6 2543
TABLE 4. Multivariable logistic regression model for outcome early
mortality
Odds
ratio 95% CI P value
Extracardiac/genetic
anomalies/syndromes
2.6 1.2-5.6 .01
Prematurity 5.4 2.3-12.4 <.001
Neonates (30 d) 6.4 1.7-24.5 .007
Infants (31 d to<1 y) 2.7 0.8-9.2 .12
RACHS-1 risk categories
1 þ 2 (reference) 1.0 — —
3 0.9 0.2-3.6 .93
4 3.6 0.9-13.7 .06
6 4.5 0.9-22.5 .06
7 (not categorized) 4.7 1.3-17.4 .02
Revision groups: reintervention for
residual lesions
Intraoperative reintervention
(reference)
1.0 — —
No reintervention 0.2 0.0-0.8 .02
Postoperative reintervention 2.1 0.5-9.5 .34
Both intraoperative and
postoperative reinterventions
5.5 0.8-37.8 .08
Early mortality is defined as death occurring 30 days from the index surgery or
death before hospital discharge if postoperative hospital length of stay>30 days. c
statistic is 0.886 for the model that does not contain revision groups, and increases
to 0.939 when revision groups are included. CI, Confidence interval; RACHS-1,
risk adjustment for congenital heart surgery.
TABLE 5. Multivariable linear regression model for outcome total
hospital cost
Regression
coefficient 95% CI P value
Extracardiac/genetic
anomalies/syndromes
1.2 1.1-1.2 <.001
Prematurity 1.4 1.3-1.5 <.001
Neonates (30 d) 1.9 1.7-2.0 <.001
Infants (31 d to<1 y) 1.3 1.2-1.4 <.001
RACHS-1 risk categories
1 (reference) 1.0 — —
2 1.4 1.3-1.5 <.001
3 2.0 1.8-2.2 <.001
4 2.4 2.1-2.7 <.001
6 3.2 2.7-3.8 <.001
7 (not categorized) 3.0 2.7-3.3 <.001
Revision groups: reintervention
for residual lesions
Intraoperative reintervention
(reference)
1.0 — —
No reintervention 0.8 0.8-0.9 .004
Postoperative reintervention 2.4 2.1-2.8 <.001
Both intraoperative and
postoperative reinterventions
2.3 1.8-3.0 <.001
Coefficient of determination is R2 ¼ 44.5% for the model that does not contain
revision groups, and increases to R2 ¼ 57.2% when revision groups are included.
CI, Confidence interval; RACHS-1, risk adjustment for congenital heart surgery.
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DRisk-adjusted subgroup analysis by age group. Restrict-
ing to patients less than 1 year of age at surgery, the relation-
ships were similar to those in the overall cohort with the
exception that for early mortality, the NO group had lower
odds of death than the IO group in both age strata, but this
was significant only for age less than 1 year.
Subgroup analysis of patients who had a major residual
lesion to compare those who had intervention postoper-
atively with those without intervention. We then per-
formed a subgroup analysis of patients with major
residual lesions who required postoperative interventions
and thosewho did not to determine factors that may be asso-
ciated with unplanned reintervention for a major residual
burden. The findings are presented in Table E6. To summa-
rize, the patients who had unplanned postoperative reinter-
ventions for major residua were significantly younger, with
a higher proportion of premature infants, and had higher
case complexity as determined by RACHS-1 risk categories
and STAT mortality categories.
Subgroup analysis of frequency-matched groups. To
help evaluate whether the differences in outcomes between
revision groups were caused by residual confounding, we
frequency matched subgroups of patients from the NO
and PO groups to the IO group to create 3 groups of equal
size that were balanced with regard to important patient
risk factors for poor outcome (age, prematurity, presence
of chromosomal or other extracardiac anomalies, surgical2544 The Journal of Thoracic and Cardiovascular Surrisk). As there were only 20 patients in the BOTH group,
it was excluded from this analysis. The results of our anal-
ysis are shown in Table E7. In these groups with a similar
profile of risk factors, the outcomes for the NO and IO
groups are similar, but the PO group has significantly higher
median hospital length of stay, postoperative AEs, and hos-
pital costs. Although the mortality rate was higher in the PO
group, this did not reach statistical significance because of
the relatively small number of deaths in each group (2 in
the NO group, 3 in the IO group, and 6 in the PO group).DISCUSSION
This study demonstrates that achieving an optimal repair,
with minimal or no residua, affects outcomes after congen-
ital cardiac surgery. Achieving this ideal endpoint may in
some instances require a second period of cardiopulmonary
support with or without a period of myocardial ischemic ar-
rest to surgically correct residual lesions. Identification of
residual lesions is essential if optimal repair is to be
achieved at the index surgery. Enhanced intraoperative
imaging that can provide information on all aspects of the
repair is an important factor in achieving optimal surgical
results before exiting the operating room. This may require
a combination of transesophageal echocardiography
(TEE) and epicardial echocardiography for structures that
may not be clearly visualized on TEE.20-22 The use of
exit angiograms for certain procedures may be agery c December 2014
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Although imaging provides visual confirmation of the
repair, clinical indicators and testing may aid in final
decision making about the adequacy of repair and the
need to reintervene, including direct measurements of
gradients and filling pressures, and monitoring of venous
and arterial saturations.25 The final decision whether to re-
intervene for residual lesions is determined by the severity
of the residua and its effect on hemodynamics and whether
reintervention on the lesion can result in an improved repair.
In some situations, it may not be anatomically possible to
achieve an optimal repair. The imperative is, however, to
achieve as optimal a repair as anatomically possible at the
index operation, as several studies have clearly shown that
optimal repairs affect not only early outcomes4-8,12 such
as mortality, AEs, and length of stay but also affect
midterm outcomes such as postdischarge mortality,
postdischarge unplanned reintervention,9,13 and even
neurodevelopmental outcomes.26 Several factors are known
to be associated with higher hospital costs,27-31 including
prematurity, age, presence of chromosomal anomalies,
and RACHS-1 risk categories. In this study, after adjusting
for baseline patient factors known to be associated with
higher hospital costs, we were able to show that identifica-
tion and repair of residual lesions in the operating room can
significantly reduce total hospital costs.
In our analysis of outcomes, we adjusted for preopera-
tive patient-specific variables. We did not use intraopera-
tive variables (eg, cardiopulmonary bypass time) because
of the strong collinearity between these variables (the IO
and BOTH revision groups as expected had significantly
longer cardiopulmonary bypass times), which would lead
to confounding. In our analysis, the PO group had signifi-
cantly poorer outcome than the IO group, however we did
show that the NO group had better outcomes compared
with the IO group. This may be because most of the low
complexity cases (RACHS-1 categories 1 and 2) were rep-
resented in the NO group. In order to account for such con-
founding, we performed additional frequency-matched
analysis outlined in Table E7. In the frequency-matched
groups, none of the baseline patient risk factors were sta-
tistically significant. Despite this, there was a significant
difference in outcomes. Postoperative hospital length of
stay was longer in the PO group; this group is more likely
to have postoperative AEs and higher median costs. The
lack of difference in mortality between the groups may
be attributable to the small number of deaths overall.
The overall mortality for our entire cohort was only
2.1% (n ¼ 39). A larger number would be needed for
this to reach statistical significance. It is well known that
in the current era of relatively low mortality rates, AE rates
and resource utilization bench marks in the form of length
of stay and costs are increasingly being used as a measure
of quality of care.The Journal of Thoracic and CarWe are currently analyzing data on intraoperative echo
and decisions on intraoperative interventions in this cohort
of patients. We have, however, performed a subgroup anal-
ysis of patients who underwent postoperative unplanned
reinterventions for major residua and those who did not un-
dergo such interventions, and we were able to demonstrate
(Table E6) that the patients who had unplanned postopera-
tive reinterventions for major residua were significantly
younger, with a higher proportion of premature infants,
and had higher case complexity as determined by
RACHS-1 risk categories and STAT mortality categories.
Subgroup analyses of patients who did and did not un-
dergo valve interventions showed that outcomes were
similar to the main cohort; the PO group had a significantly
worse outcome than the IO group. Comparing the NO group
with the IO groups, although length of hospital stay was
significantly lower, but there was no significant difference
in AEs, mortality, or costs. Similarly, when we performed
a subgroups analysis of patients less than 1 year of age
and those more than 1 year of age, the PO group had signif-
icantly worse outcomes for infants less than 1 year of age.
However, when the IO group was compared with the NO
group, there was no difference in postoperative hospital
length of stay and AEs, although mortality and costs were
lower in the NO group.
On reviewing the use of intraoperative imaging in this
cohort, 129 (6.8%) patients had no intraoperative echocar-
diograms, of whom 11 (8.5%) had major residua on postop-
erative imaging, 10 (7.7%) of whom required PO revision.
In addition, 34 (1.8%) patients had incomplete echos, 7
(20.5%) of whom hadmajor residua on postoperative imag-
ing, 6 (17.8%) of whom required PO revision. This finding
clearly supports the need for intraoperative assessment of
adequacy of repair and detection of residual lesions. The
trend in our center is to obtain intraoperative imaging
(either a transesophageal or epicardial echocardiogram) un-
less contraindicated for anatomic or hemodynamic reasons,
and when necessary to supplement this information with
direct pressure measurements and saturation data. More
than two thirds of our IO revisions were related to valve
interventions. The hemodynamic conditions immediately
after cardiopulmonary bypass may make accurate measure-
ments of the severity of valvular regurgitation and stenosis
difficult, however, imaging often provides useful informa-
tion on anatomic variants that are likely to worsen with
time (eg, valvular regurgitation secondary to prolapse of a
leaflet). About 40% of PO revisions were valve related.
We are currently analyzing intraoperative echocardio-
graphic findings and postoperative echocardiographic find-
ings with the aim of developing a score that will help to
determine the need for intraoperative revisions and predict
postoperative revisions. Despite our best efforts, there
remain subgroups of patients with complex anatomy in
whom an optimal repair may not be achievable.diovascular Surgery c Volume 148, Number 6 2545
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DThis study, despite being a prospective analysis of
consecutive patients, is limited by the fact that it reflects
data from a single institution. The generalizability of these
findings to other national and international centers will
require a prospective multicenter study.
In summary, identification and correction of residual le-
sions in the operating room is associated with improved out-
comes. Enhanced intraoperative imaging, which can
provide information on all aspects of a repair, is an impor-
tant factor in achieving optimal surgical results before exit-
ing the operating room.References
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Dr Emile Bacha (New York, NY). Meena, a very nice presenta-
tion. It is very rare in heart surgery that one can confirm a so-called
dogma, so it is nice when you see that happening. Here you are
confirming, in a prospective manner no less, that a good or optimal
procedure achieved during the first bypass run achieves the best
possible results. You also showed that intraoperative recognition
and repair of residual defects is superior in terms of outcomes to
postoperative recognition and repair. I do not think anybody will
argue with your findings, but it is still nice to see them proven
scientifically. Your findings were particularly true for premature
neonates and young infants and for higher risk categories.
Although your study was focused more on the intraoperative
versus postoperative group, that is, the patients who underwent
re-repair during the first operation compared with the second oper-
ation, I was really interested in the comparison you had between
the NO group, no re-repair, versus the intraoperative group,gery c December 2014
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C
H
Dbecause you could look at the data differently. You had a higher
mortality in the intraoperative re-repair group versus the NO group
even though you had the same length of hospital stay, but that may
be determined by the patients who died and therefore you had a
lower length of hospital stay. I always tended to think about these
patients, those who undergo an immediate re-repair, as being equal
in terms of prognosis to those who had a first excellent repair.
Could you comment on that, please?
Dr Nathan. I need to mention that the NO group included
patients who underwent repair on cardiopulmonary bypass and
those who had non–cardiopulmonary bypass procedures such as
shunts and unifocalization, and the NO group had a much lower
rate of adverse events and mortality because they represented the
larger group of patients among the entire cohort. If we compared
just the patients who had undergone operations on cardiopulmo-
nary bypass, the difference would probably be much lower, and
we are in the process of analyzing that data.
Dr Bacha. So you are saying the groups are not well matched?
Dr Nathan. Not adequately matched, yes.
Dr Bacha.Another surgical dogma is that the enemy of good is
better, and that is one of the most difficult things a surgeon has to
decide in the operating room. If you have, let’s say, a mild or
moderate defect but your patient is doing okay, do you go back
on bypass and fix it versus do you accept it? That is a very difficult
decision to make. Can your data help us decide, maybe from what
you know on the technical performance score database, on that
particular question?
Dr Nathan. I totally agree with you that the enemy of good is
better, and we are actually in the process of developing a score
that will help us determine which residual lesions need revision
in the operating room versus those that can be followed. Most
postoperative revisions were related to valves, and I think this is
a group that needs to be studied individually rather than as part
of a large cohort. We are in the process of collecting and analyzing
data from this group of patients.
Dr Bacha. The third question is regarding the issue of timing of
the diagnosis of the residual defect, because I think it makes a
difference whether you are reoperating the next day for a major
residual defect versus 2 weeks or before discharge, let’s say. Do
you have any comments on the timing? Was that a factor?
Dr Nathan. The numbers are fairly small, so we could not look
at each individual time point of reintervention, but most of the
postoperative revisions were more than 48 hours after surgery.
Dr Bacha. Did that make a difference?
Dr Nathan.We have not looked at that specifically because the
numbers were too small to do a meaningful analysis.
Dr Bacha. And the last question. The most common type of re-
repair was a left AV valve repair. You would expect that, especially
if you have a large valve practice. Now, you could argue that if you
are doing complex leftAVvalve repairs, sometimes you simply have
to come off bypass, look at your TEE, and then go back on bypass
almost in a planned manner. Those were counted as re-repairs.
Do you think you should differentiate between valve re-repairs
versus nonvalve re-repairs such as residual aortic arch
obstructions, or residual VSDs that may potentially carry a worse
prognosis?
Dr Nathan. Thank you very much. I think that is really worth
exploring and we will proceed to do so.The Journal of Thoracic and CarDr Christian Pizarro (Wilmington, Del). Meena, a great
presentation and very interesting study. I wonder if you had the
opportunity to look at the use of extracorporeal membrane
oxygenation (ECMO) in those patients who had residual lesions
who were intervened on postoperatively? Not infrequently some-
times there are some of those lesions, the circulation is precarious,
and patients are not in good condition. Did you explore about how
that use of ECMO early with a plan to go to the operating room,
let’s say, the next day or so could have affected the outcome?
Dr Nathan. We did look at ECMO, but it was included as a
composite in the adverse events, because, again, the numbers in
each of the groups were small so that comparison using an
individual adverse event was difficult.
Dr Pizarro. And then just briefly, among those patients who
had a postoperative intervention, howmany of those had a residual
lesion that was identified in the operating room but deemed
probably not to be important enough? That goes to the judgment
at the time, should I leave this, should I act on it?
Dr Nathan. Among the valve repairs, at least on intraoperative
assessment, the regurgitation was usually at least a grade or two
lower than in later postoperative echocardiograms, so those could
not be picked up intraoperatively. Thus several valve repairs that
occurred postoperatively had an increase in grade of regurgitation
that necessitated their repair.
Dr Mark Danton (Glasgow, Scotland, UK). From your data,
obviously it is best to repair any residual lesion at the time of
the first operation. So with respect to the residual lesions that
required repair at a second or subsequent operation, were those
new lesions, first identified in the postoperative phase, or were
they lesions recognized at initial surgery but progressed over
time, or finally was the gravity of lesion underappreciated at the
time of intraoperative assessment. If it were the case that the
significance of the residual lesion was underestimated at surgery,
is there a better way of identifying them and their significance at
the first operation so that you do not have to deal with them at a
subsequent operation?
Dr Nathan. A small percentage of the valve re-repairs postopera-
tively were related to an increase in regurgitation grade related to
either a torn stitch or new additional regurgitation that was not identi-
fied in the operating room.So I think intraoperative assessment should
not only include a good echo, it should also include clinical assess-
ment, which is what all of us do in the operating room. And we are
in the process of trying to define the intraoperative echo findings
that match the postoperative echo findings that will identify which
intraoperative echo findings require a revision. We are currently in
the process of comparing intraoperative echos to postoperative echos
to arrive at cut points that will define better whenwe should intervene
in the operating room compared with postoperatively.
Dr Matthias Siepe (Freiburg, Germany). Excellent study.
Thank you. I am a little bit confused about those patients who
required a catheter-based intervention. In which group did you
put those patients? Or should there be a fifth group with
catheter-based reinterventions?
Dr Nathan. Currently these patients are included in the
postoperative revisions, because some of the patients did require
postoperative pulmonary artery stenting or dilation. The numbers
are fairly small, but wewill try and analyze that group as a separate
group and see if there is a difference.diovascular Surgery c Volume 148, Number 6 2547
FIGUREE1. Association between revision groups and outcomes.NO, No revisions; IO, intraoperative revisions; PO, postoperative revisions; BOTH, both
intraoperative and postoperative revisions.
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TABLE E2. Postoperative operative revisions for residual lesions
(n ¼ 128)
Type of repair n Type of repair n
Aortic valve repair 5 Main pulmonary artery
ligation for dual PBF
2
Aortic valve balloon dilation 1 Mustard baffle revision 1
Aortic valve replacement 2 Orthotopic heart transplant 1
Atrial septal defect balloon
dilation/stent
4 Pulmonary artery band 1
Azygos stent 1 Pulmonary artery band
revision
1
Bidirectional Glenn 2 partial anomalous pulmonary
venous return revision
1
Bidirectional Glenn balloon
dilation
1 PDA ligation 2
Bidirectional Glenn
take-down
1 Permanent pacemaker 26
Branch pulmonary artery
balloon dilation/stent
24 Pulmonary vein balloon
dilation
12
Bronchus dilation/stenting 1 Right atrioventricular valve
repair
9
Blalock-Taussig shunt
balloon dilation/stent
2 Right atrioventricular valve
replacement
3
Blalock-Taussig revision/
conversion/insertion
5 Residual atrial septal defect
repair
3
Coil APC/VVC (for failed
ligation in to operating
room)
2 Residual ventricular septal
defect repair
5
Fenestrated atrial septal
defect closure
1 Right ventricular outflow
tract revision
8
Fontan fenestration closure 1 Ross 1
Fontan Fenestration stent 1 Right ventricular outflow
tract stent
1
Fontan stent 1 Sano balloon dilation/stent 2
Fontan take-down 1 Shunt milking or clipping 4
Left atrioventricular valve
balloon dilation
2 Superior vena cava repair 1
Left atrioventricular valve
repair
11 Superior vena cava stent 6
Left atrioventricular valve
replacement
10 Total anomalous pulmonary
venous connection baffle
revision
1
Left circumflex balloon
dilation
1 Ventricular assist device 1
Left ventricular outflow
tract myectomy
1
Some patients had more than 1 reintervention. APC, Aortopulmonary collaterals;
VVC, veno-venous collaterals; PBF, pulmonary blood flow; PDA, patent ductus
arteriosus.
TABLE E1. Intraoperative revisions for residual lesions (n ¼ 81)
Type of repair n Type of repair n
Aortic root repair 1 Partial anomalous pulmonary
venous return patch
revision
3
Aortic valve repair 9 Pulmonary valve
repositioning
1
Ascending aortic patch 1 Pulmonary vein baffle in
Senning
1
Bidirectional Glenn
(after Cone)
1 Pulmonary vein vent site
repair
1
Branch pulmonary artery
augment
2 Right atrioventricular valve
repair
14
Blalock-Taussig shunt
revision
1 Residual left ventricular
outflow tract obstruction
5
Conversion to transannular
patch
3 Residual ventricular septal
defect
14
Coronary button revision 3 Right ventricular outflow
tract revision
3
Left atrioventricular valve
repair
23 Right ventricle-pulmonary
artery conduit
1
Left atrioventricular valve
replacement
1 Superior vena cava stenosis
repair
1
Left ventricle-aorta baffle
enlargement
3 Ventricular septal defect
patch fenestration
1
Main pulmonary artery patch 1
Some patients had more than 1 reintervention.
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TABLE E3. Both intraoperative and postoperative revisions for residual lesions (n ¼ 19)
Intraoperative reintervention (n ¼ 19; same patients) Postoperative reintervention (n ¼ 19; same patients)
Type of repair n Type of repair n
Atrial septal defect closure 1 Atrioventricular valve repair/replacement 7
Atrioventricular valve re-repair 14 Damus-Kaye-Stansel revision 1
Coronary button revision 1 Pulmonary artery band take-down 1
Damus-Kaye-Stansel revision for coronary malperfusion 1 Pulmonary artery dilation 3
Residual ventricular septal defect closure or enlargement of patch 2 Permanent pacemaker 10
Systemic vein re-repair 1 Residual ventricular septal defect/atrial septal defect 2
Ventricular septal defect fenestration 1 Ross 1
Some patients had more than 1 reintervention.
TABLE E4. Unadjusted associations between outcomes: postoperative hospital length of stay, postoperative adverse events, early mortality, total
hospital costs, and patient risk factors
Postoperative hospital
length of stay,
median (IQR) days
Postoperative
adverse events, n (%)
Early mortality,
n (%)
Total hospital costs,
median (IQR) US$
Extracardiac/genetic anomalies/syndromes
Yes (n ¼ 390) 8 (5, 17) 26 (7) 17 (4) 50,979 (36,898, 117,471)
No (n ¼ 1496) 7 (4, 12) 74 (5) 22 (1) 46,608 (32,795, 85,687)
Prematurity
Yes (n ¼ 145) 13 (7, 29) 29 (20) 15 (10) 88,809 (46,495, 200,018)
No (n ¼ 1741) 7 (4, 12) 71 (4) 24 (1) 46,048 (32,924, 85,369)
Age
Neonates (n ¼ 315) 16 (10, 27) 47 (15) 21 (7) 111,546 (79,540, 176,315)
Infants (n ¼ 582) 7 (5, 14) 33 (6) 14 (2) 48,486 (35,922, 92,088)
Children (n ¼ 989) 5 (4, 8) 20 (2) 4 (<1) 39,373 (29,060, 57,610)
RACHS-1 risk categories
1 (n ¼ 164) 3 (3, 4) 0 (0) 0 (0) 23,759 (22,235, 26,383)
2 (n ¼ 586) 5 (4, 7) 11 (2) 4 (1) 38,057 (30,822, 50,245)
3 (n ¼ 676) 8 (5, 13) 24 (4) 6 (1) 52,701 (38,366, 87,610)
4 (n ¼ 208) 12 (8, 21) 27 (13) 13 (6) 90,416 (60,666, 146,345)
6 (n ¼ 71) 26 (18, 41) 18 (25) 7 (10) 154,915 (122,687, 250,282)
7 (n ¼ 181) (not categorized) 11 (7, 25) 20 (11) 9 (5) 86,190 (49,902, 170,395)
STAT mortality categories
1 (n ¼ 650) 5 (4, 6) 6 (1) 1 (<1) 33,389 (26,327, 43,800)
2 (n ¼ 525) 6 (5, 10) 14 (3) 2 (<1) 44,104 (34,526, 70,601)
3 (n ¼ 183) 9 (7, 16) 9 (5) 3 (2) 66,888 (44,487, 102,814)
4 (n ¼ 376) 12 (7, 21) 44 (12) 20 (5) 90,552 (60,390, 148,551)
5 (n ¼ 105) 20 (14, 33) 23 (22) 10 (10) 136,715 (96,206, 215,038)
6 (n ¼ 47) (not categorized) 10 (7, 18) 4 (9) 3 (6) 85,554 (47,365, 136,999)
IQR, Interquartile range; RACHS-1, risk adjustment in congenital heart surgery; STAT, Society of Thoracic Surgeons–European Association for Cardio-Thoracic Surgery
mortality categories.
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TABLE E5. Subgroup analysis of outcomes: postoperative hospital length of stay, postoperative adverse events, early mortality, and total hospital
costs based on patient age and valve intervention at index surgery
Postoperative hospital
length of stay,
median (IQR) days P value
Postoperative
adverse
events,% P value
Early
mortality,% P value
Total hospital costs,
median (IQR) US$ P value
Revision group
None (1658) 6 (4, 11) <.001 2.9 <.001 0.8 <.001 44,504 (32,134, 78,342) <.001
Intraoperative (81) 7 (5, 11) 3.7 3.7 49,427 (37,552, 81,592)
Postoperative (128) 26 (14, 63) 33.6 14.8 204,750 (99,061, 427,594)
Valve interventions
None (842) 6 (5, 10) <.001 1.9 <.001 0.4 <.001 44,073 (34,173, 72,493) <.001
Intraoperative (61) 6 (5, 10) 3.3 3.3 44,919 (37,552, 65,311)
Postoperative (65) 21 (12, 56) 23.1 7.7 169,384 (86,990, 448,581)
No valve interventions
None (816) 7 (4, 12) <.001 3.9 <.001 1.2 <.001 46,092 (29,237, 83,393) <.001
Intraoperative (20) 12 (7, 19) 5.0 5.0 94,171 (43,226, 131,541)
Postoperative (63) 33 (15, 63) 44.4 22.2 211,033 (134,530, 418,492)
Age<1 y
None (263) 15 (10, 24) <.001 8.8 <.001 2.3 <.001 100,835 (76,204, 141,127) <.001
Intraoperative (9) 13 (11, 19) 22.2 22.2 104,879 (92,281, 254,696)
Postoperative (39) 35 (21, 57) 46.2 25.6 244,920 (172,280, 396,683)
Age 1-17 y
None (1395) 6 (4, 9) <.001 1.8 <.001 0.5 <.001 40,034 (30,465, 59,459) <.001
Intraoperative (72) 7 (5, 10) 1.4 1.4 45,994 (37,101, 68,260)
Postoperative (89) 19 (12, 68) 28.7 10.1 146,682 (87,297, 452,752)
IQR, Interquartile range.
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TABLE E6. Characteristics and outcomes of patients with major residual lesions who required postoperative interventions, those who did not
require intervention, and others
Major residual lesions
with intervention
before discharge
Major residual lesions
with no intervention
before discharge All others P value
Number in group 145 98 1643
Median age, y (range) 0.5 (1 d-15.5) 0.9 (1 d-17.6) 1.4 (1 d-17.9) <.001
Prematurity, n (%) 20 (14) 12 (12) 113 (7) .004
Extracardiac/genetic anomalies/syndromes 36 (25) 26 (27) 328 (20) .12
RACHS-1 risk category, n (%)
1 (164) 1 (1) 0 (0) 163 (10) <.001
2 (586) 17 (12) 19 (19) 550 (33)
3 (676) 55 (38) 57 (58) 564 (34)
4 (208) 27 (19) 13 (13) 168 (10)
6 (71) 13 (9) 3 (3) 55 (3)
7 (181) (not categorized) 32 (22) 6 (6) 143 (9)
STAT mortality category, n (%)
1 (650) 9 (6) 18 (18) 623 (38) <.001
2 (525) 33 (23) 40 (41) 452 (28)
3 (183) 14 (10) 15 (15) 154 (9)
4 (376) 66 (46) 19 (19) 291 (18)
5 (105) 17 (12) 5 (5) 83 (5)
6 (47) (not categorized) 6 (4) 1 (1) 40 (2)
Median postoperative hospital length of stay,
d (25th, 75th percentiles)
23 (13, 56) 9 (5, 17) 6 (4, 10) <.001
Postoperative adverse events, n (%) 47 (32.4) 9 (9.2) 44 (2.7) <.001
Early mortality, n (%) 23 (15.9) 5 (5.1) 11 (0.7) <.001
Median total hospital costs,
US$ (25th, 75th percentiles)
203,572 (99,255, 402,592) 61,141 (42,758, 115,123) 44,104 (31,985, 76,899) <.001
RACHS-1, Risk adjustment in congenital heart surgery; STAT, Society of Thoracic Surgeons–European Association for Cardio-Thoracic Surgery mortality categories.
TABLE E7. Patient characteristics and outcomes by 3 revision groups (BOTH group excluded)
No revisions
Intraoperative revision
of residual lesion
Postoperative revision
of residual lesion P value
Number in group 81 81 81
Median age, y (range) 2.2 (1 d-16.6) 1.9 (1 d-16.5) 1.3 (1 d-15.5) .43
Prematurity, n (%) 5 (6) 5 (6) 7 (9) .86
Extracardiac/genetic anomalies/syndromes 21 (26) 21 (26) 21 (26) 1.0
RACHS-1 risk category, n (%)
1 (7) 3 (4) 3 (4) 1 (1) .69
2 (68) 25 (31) 25 (31) 18 (22)
3 (125) 41 (51) 41 (51) 43 (53)
4 (26) 8 (10) 8 (10) 10 (12)
6 (0) 0 (0) 0 (0) 0 (0)
7 (17) (not categorized) 4 (5) 4 (5) 9 (11)
Median postoperative hospital length of stay,
d (25th, 75th percentiles)
6 (4, 9) 7 (5, 11) 18 (12, 44) <.001
Postoperative adverse events, n (%) 36 (3.7) 3 (3.7) 21 (26) <.001
Early mortality, n (%) 2 (2.5) 3 (3.7) 6 (7.4) .40
Median total hospital costs,
US$ (25th, 75th percentiles)
44,118 (31,062, 66,765) 49,427 (37,552, 81,592) 140,430 (86,990, 341,506) <.001
Samples of patients with no revision or postoperative revision were selected to have similar distributions of risk factors to the group with intraoperative revision. RACHS-1, Risk
adjustment in congenital heart surgery.
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